MedKoo Cat#: 585087 | Name: RX-RA 69

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RX-RA 69 is a pyrimido-pyrimidine derivative and PDA-inhibitor which inhibits tumor cell induced platelet aggregation in vitro.

Chemical Structure

RX-RA 69
RX-RA 69
CAS#77749-49-6

Theoretical Analysis

MedKoo Cat#: 585087

Name: RX-RA 69

CAS#: 77749-49-6

Chemical Formula: C21H25N7OS

Exact Mass: 423.1841

Molecular Weight: 423.54

Elemental Analysis: C, 59.55; H, 5.95; N, 23.15; O, 3.78; S, 7.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
RX-RA 69; RX-RA69; RX-RA-69
IUPAC/Chemical Name
Pyrimido(5,4-d)pyrimidine, 4-(4-morpholinyl)-8-((phenylmethyl)thio)-2-(1-piperazinyl)-
InChi Key
LUGKHBNNJJSVLE-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H25N7OS/c1-2-4-16(5-3-1)14-30-20-18-17(23-15-24-20)19(27-10-12-29-13-11-27)26-21(25-18)28-8-6-22-7-9-28/h1-5,15,22H,6-14H2
SMILES Code
C1(N2CCNCC2)=NC(N3CCOCC3)=C(N=CN=C4SCC5=CC=CC=C5)C4=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 423.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Agarwal KC, Buckley RS, Parks RE Jr. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences. Thromb Res. 1987 Jul 15;47(2):191-200. PubMed PMID: 2821650. 2: Lichtner RB, Hutchinson G, Wedderburn N, Hellmann K. Antiplatelet pyrimido-pyrimidines and metastasis. Cancer Treat Rev. 1985 Dec;12(4):221-34. Review. PubMed PMID: 3009013. 3: Machleidt C, Rose P, Mittmann U. Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69. Thromb Res. 1985 Mar 1;37(5):595-604. PubMed PMID: 2984803. 4: Lichtner R, Wedderburn N. Enhancement of the immune response to sheep erythrocytes in mice by phosphodiesterase-inhibiting dipyridamole derivatives. J Immunopharmacol. 1984;6(1-2):43-55. PubMed PMID: 6088639. 5: Lichtner R, Haarmann W. Antimetastatic action of RX-RA 69, a new potent PDE-inhibitor in the Lewis lung carcinoma of the mouse. Prog Clin Biol Res. 1982;89:131-41. PubMed PMID: 6287486.